(Q39561094)

English

Orphan drug legislation: lessons for neglected tropical diseases

scientific article published on January 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Orphan drug legislation: lessons for neglected tropical diseases (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

1 reference

based on heuristic

inferred from title

Michael R. Reich

object named as

Michael R Reich

3

0 references

author name string

Stefano Villa

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Amelia Compagni

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

International Journal of Health Planning and Management

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

27-42

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccine advance-purchase agreements for low-income countries: practical issues.

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of an orphan drug by a start-up company. MetroGel for rosacea

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Translating epoetin research into practice: the role of government and the use of scientific evidence

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Success rates for new drugs entering clinical testing in the United States

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Availability and affordability of treatment for Human African Trypanosomiasis

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

The distribution of sales revenues from pharmaceutical innovation

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Two decades of orphan product development

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Adopting orphan drugs--two dozen years of treating rare diseases.

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Engaging biotechnology companies in the development of innovative solutions for diseases of poverty

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Orphan drug development is progressing too slowly

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmaceuticals and the developing world

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

New TB vaccine granted orphan drug status

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Malaria vaccine developments

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Are novel drugs more risky for patients than less novel drugs?

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Access to essential drugs in poor countries: a lost battle?

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Mectizan Donation Program: evaluation of a public-private partnership

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

The global drug gap.

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Developing drugs for developing countries

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

EU to review rare disease drugs market exclusivity

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug development for neglected diseases: a deficient market and a public-health policy failure

1 reference

https://api.crossref.org/works/10.1002%2FHPM.930

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HPM.930

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39561094&oldid=2132816514"